C4 Therapeutics, Inc. CCCC
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $13.00 (+283.5% upside)
Key Stats
- Today's Range
- $3.38 – $3.48
- 50-Day Range
- $3.31 – $4.38
- 52-Week Range
- $1.69 – $5.17
- Volume
- 1.63 million shs
- Average Volume
- 2.14 million shs
- Market Cap
- $417.06 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.69
- Price / Sales
- 11.90
Short Interest
- Short Interest
- 0.29%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $35.04 million
- Net Income
- $-101,416,000
- Net Margin
- -289.44%
- Return on Equity
- -41.02%
- Debt-to-Equity
- —
About C4 Therapeutics, Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Related Stocks
Compare head-to-head: CCCC vs AMGN·CCCC vs MRNA·CCCC vs HALO·CCCC vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.